Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Non-Invasive Saliva Test Measures Tetanus Immunity in Children within 15 Minutes

By LabMedica International staff writers
Posted on 10 Jul 2024

Tetanus is a bacterial infection that can be deadly but is preventable through vaccination. More...

Yet, over 20 million children globally do not receive essential childhood vaccinations, and the COVID-19 pandemic caused the coverage of the diphtheria-tetanus-pertussis vaccine to drop to its lowest in 15 years, placing more individuals at risk of severe illnesses. While there has been a general decline in tetanus worldwide, the disease still results in avoidable deaths in several low-middle-income countries (LMICs). In response, experts are now developing a non-invasive saliva test that - within 15 minutes - could identify children in the Global South who lack immunity to tetanus and may have missed crucial vaccinations.

Researchers at University of Birmingham (Birmingham, UK;) are working on a low-cost lateral flow test that allows for easy, quick immunity testing without the need for blood draws, which is the current standard. After initial laboratory tests, this new method will be put to the test in Rwanda. There, researchers will evaluate its effectiveness in real-world conditions and gauge its acceptance within the local community. The test is designed for use in various settings, from outreach programs and community gatherings to clinics and hospitals, and could significantly enhance access to immunity testing in areas where it's challenging to assess protective status and gather sero-epidemiological data. Being non-invasive and saliva-based, it eliminates the complications and costs associated with blood sampling, which is particularly beneficial for children. The researchers plan to extend trials of this test to other LMICs to measure immunity levels across different populations and support vaccination monitoring and strategy development.

“Our test shows if a person has protection against tetanus within 15 minutes. It can help identify individuals who are not protected and need vaccination,” said Dr. Jennifer Heaney, Research Fellow, University of Birmingham. “As tetanus vaccination features in all combined immunizations alongside other serious diseases, if an individual is unprotected against tetanus, they are also likely to be missing protection against other serious vaccine-preventable diseases. The test therefore can measure tetanus immunity but could also help identify broader gaps in vaccine provision.”

Related Links:
University of Birmingham 

 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.